Gene mutation can increase women's risk of pancreatic cancer

Share This Post

A recent study published in the journal Cellular and Molecular Gastroenterology and Hepatology showed that a gene mutation called ATRX may lead to an increased risk of pancreatitis and pancreatic cancer in women. This study marks the first discovery of sex-specific genetic risk factors for pancreatic cancer.

The team used a preclinical model to examine the effect of ATRX mutations on the adult pancreas. They deleted the ATRX gene and then studied its effect on pancreatic cancer susceptibility. The team found that the deletion of the ATRX gene in women increased the susceptibility to pancreatitis-related pancreatic damage and accelerated the progression of pancreatic cancerIn men, ATRX mutations do not increase the risk of pancreatic damage, and actually slow the progression of pancreatic cancer.

The team ‘s preclinical results were compared with human samples from the International Cancer Genome Alliance database, which includes whole-genome sequence analysis of 729 patients. The research team found that 19% of patients carry mutations in the length of the ATRX gene, including non-coding regions, of which 70% are female. Although most mutations do not seem to disrupt the ATRX protein sequence, mutations predicted to affect ATRX function occur almost exclusively in women.

Lawson scientist and associate professor Dr. Chris Pin said, “Pancreatic cancer is a very devastating disease that is often diagnosed at an advanced stage. Patients usually do not respond to existing therapies, and the average lifespan of patients is after diagnosis Less than 6 months. “Pancreatitis is a disease characterized by inflammation of the pancreas and one of the most important risk factors for developing pancreatic cancer. Although further research is needed, women with pancreatitis may one day be identified as a high-risk group, and this gene mutation should be screened.

In a follow-up study, Dr. Pin will work with French researchers to study patient tumor samples in a new preclinical model. Their goal is to better understand the mechanism of ATRX mutations as a gender-specific risk factor. In order to develop better diagnosis and treatment methods for women carrying this mutation.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy